210 related articles for article (PubMed ID: 30298129)
21. Surgery Versus ATMPs: An Example From Ophthalmology.
Magrelli FM; Merra A; Pellegrini G
Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848
[TBL] [Abstract][Full Text] [Related]
22. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
23. From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU.
Pellegrini G; Lambiase A; Macaluso C; Pocobelli A; Deng S; Cavallini GM; Esteki R; Rama P
Regen Med; 2016 Jun; 11(4):407-20. PubMed ID: 27091398
[TBL] [Abstract][Full Text] [Related]
24. Current landscape of clinical development and approval of advanced therapies.
Iglesias-Lopez C; Agustí A; Vallano A; Obach M
Mol Ther Methods Clin Dev; 2021 Dec; 23():606-618. PubMed ID: 34901306
[TBL] [Abstract][Full Text] [Related]
25. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
26. Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P
Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565
[TBL] [Abstract][Full Text] [Related]
27. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
28. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
Viswanathan S; Bubela T
Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
[TBL] [Abstract][Full Text] [Related]
29. Translational research on advanced therapies.
Belardelli F; Rizza P; Moretti F; Carella C; Galli MC; Migliaccio G
Ann Ist Super Sanita; 2011; 47(1):72-8. PubMed ID: 21430343
[TBL] [Abstract][Full Text] [Related]
30. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
31. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
32. Medicinal Product Regulation: Portugal׳s Framework.
Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
[TBL] [Abstract][Full Text] [Related]
33. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
34. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
35. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.
Watanabe N; Yano K; Tsuyuki K; Okano T; Yamato M
Mol Ther Methods Clin Dev; 2015; 2():14066. PubMed ID: 26052534
[TBL] [Abstract][Full Text] [Related]
36. Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them.
Rousseau CF; Mačiulaitis R; Śladowski D; Narayanan G
Front Med (Lausanne); 2018; 5():158. PubMed ID: 29911104
[TBL] [Abstract][Full Text] [Related]
37. [A proposal for reforming psychologists' training in France and in the European Union].
Bouchard JP
Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
[TBL] [Abstract][Full Text] [Related]
38. Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.
Driscoll D; Farnia S; Kefalas P; Maziarz RT
Stem Cells Transl Med; 2017 Aug; 6(8):1723-1729. PubMed ID: 28749065
[TBL] [Abstract][Full Text] [Related]
39. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
40. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
